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 PARP inhibitors: an interesting pathway also for non-small cell lung cancer? 
Giaj Levra M, Olaussen KA, Novello S, Soria JC 
 
Abstract: Treatment of lung cancer is improving, also based on the identification of 
molecular characteristics of the tumor, of which some already constitute promising targets. 
One of the molecular characteristics thought to play an important role in lung cancer is 
DNA repair dysfunctionality. Deregulated expression of DNA repair proteins, such as PARP, 
has been studied in lung cancer as a possible biomarker and clinically useful target, but the 
literature remains relatively poor. Pharmacological inactivation of PARP has allowed the, 
identification of a synthetic lethality with a second DNA repair protein such as BRCA1, but 
has also shown the potential to sensitize tumors to commonly used cytotoxic agents. The 
current manuscript reviews data regarding PARP in the context of DNA repair and its 
different pathways, as well as the clinical data generated until now with PARP inhibitors. A 
deeper understanding of the DNA damage response in lung malignancies, and particularly 
a clarification of the crosstalk between DNA repair functionality and genetic stability, is the 
key to optimize the development of PARP inhibitors in the setting of NSCLC. 
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INTRODUCTION 
Damaged DNA and subsequent genomic instability accompany the malignant 
transformation of cells and subsequent metastatic processes. In parallel, a number of 
tumors are characterized by the  loss of functionality in one or several DNA repair 
pathways, such as in a subset of breast and ovarian cancers (BRCA1 or BRCA2 
repression/mutation, which are essential genes in the homologous recombination repair 
pathway), in colon cancer (methylated promoter/loss of hMLH1 or MSH2 expression, 
essential proteins in the mismatch repair pathway), in gliomas (methylated promoter/loss 
of MGMT expression) and in lung cancer (loss of ERCC1 expression). 
Damaged DNA is signaled through a DNA Damage Response (DDR) mechanism allowing cell 
cycle regulation, apoptotic regulation and/or a rapid processing of insults by the DNA 
repair machinery. Poly-ADP ribosylation (PAR) is a post-translational modification of 
proteins or histones that is catalyzed mainly by the poly- ADP ribose polymerase 1 (PARP1) 
and PARP2. It is believed that the PAR process is an important early cellular response to 
DNA damage. The process causes chromatin decondensation around the damage sites. 
This “activation” allows the recruitment of repair machineries such as the base excision 
repair (BER) complexes. The system thereby accelerates DNA repair, particularly in the 
case of single-stranded breaks (SSBs) [1]. PARP1 also seems to affect double-strand break 
(DSB) repair, since PARP1 deficient cells are hypersensitive to DSB inducing agents. Indeed, 
PARP is activated at stalled replication forks allowing Homologous Recombination Repair 
(HRR) and mediates Mre11-dependent replication restart [2]. 
In this review, we enumerate the different PARP inhibitors that have been evaluated 
clinically in lung cancer. Compared to breast and ovarian cancers, the idea of using PARP 
inhibitors in lung cancer is not related to BRCA1/2 mutations, since these are not found. 
However, in tumors carrying intrinsically high genomic instability (or high DNA repair 
dysfunctionality), targeting PARP might induce a “saturation” of the systems controlling 
DNA damage with subsequent cell death. A second strategy has been to evaluate the 
combination of PARP inhibitors with DNA interacting chemotherapeutic agents such as 
platinum compounds. Indeed, pharmacological PARP inhibition increases platinum adduct 
accumulation in NSCLC cells suggesting a slow-down of platinum DNA-adduct repair 
capacity, which eventually potentiates the efficacy of platinum- based chemotherapy 
independently from p53-status [3,4]. 
 
PARP IN THE CONTEXT OF SINGLE STRAND BREAK REPAIR 
PARP is an essential protein in the BER pathway, which is responsible of the removal of 
small (non bulky) base damages with subsequent single strand breaks (SSBs). These 
damages on one base of the DNA might originate from endogenous insults (mainly 
oxidative modifications, but also deamination or hydrolysis of glycosyl DNA bonds leading 
to loss of the entire base) or have an exogenous origin (X-rays, monofunctional alkylating 
agents, or antimetabolites) [5]. The initial step of BER is the removal of the damaged base 
by a DNA glycosylase, which induces the formation of an abasic (apurinic/apyrimidinic) site [6]. 
The abasic site is recognized by APE1 endonuclease in association with PARP and XRCC1. PARP-
mediated ribosylation largely modifies the structure of histones and other proteins surrounding 
the lesion [7]. The abasic site is processed by APE1, whereas XRCC1, which is one of the acceptor 
proteins of  the ADP-ribosyl polymers, recruits DNA polymera β that fills in the lacking single 
nucleotide (short patch BER). Less frequently, a longer 2-15 nucleotides repair is involved (long-
patch BER) with the contribution of other proteins such as PCNA and FEN1. In both long and short 
patch BER, the final ligation is performed by DNA ligase III. Noteworthy, recent work has linked the 
BER pathway to the nucleotide excision repair (NER) pathway with the implication of DNA 
structure-specific nucleases such as ERCC1 [8,9]. 
The role of PARP in BER-mediated SSB repair appears as essential. PARP is rapidly recruited to 
damaged DNA thereby activating its catalytic domain that catalyze both the covalent transfer of 
the ADP-ribose moiety of nicotinamide adenine nucleotides (NAD+) to a variety of nuclear protein 
acceptors, a reaction that consumes NAD+ and thereby ATP (Fig. 1) [10]. The reaction creates 
branched polymers of 60 to 80 ADP-ribose units on PARP itself that PARP transfers to other 
acceptor proteins such as XRCC1. Since the polymers of ADP-ribose units are negatively charged, 
they cause an electrostatic repulsion between poly-ADP  ribosylated proteins and DNA with a 
subsequent local relaxation of DNA structures [11]. This phenomenon is thought to improve the 
accessibility of DNA to repair enzymes [12].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Function of PARP and consequences of PARP inhibitors. Upon spontaneous or induced DNA single strand 
breaks or other therapeutically induced lesions (interstrand cross-links are not shown for the sake of clarity), PARP1 is 
recruited to DNA where it immediately polymerizes branched ADP-ribosyl units on itself, which allows the recruitment 
of DNA repair proteins such as XRCC1 in the base excision repair (BER) pathway (A). If the level of DNA damage is very 
high, the subsequent NAD/ATP depletion due to Poly(ADP-ribosyl)ation will trigger necrotic cell death. The use of PARP 
inhibitors in cancer cells eventually leads to DSBs during replication. These DSBs are repaired by the homologous 
recombination (HR) pathway in cells containing active BRCA1/2 proteins (B) or by non-homologous end joining (NHEJ). 
The balance between HR and NHEJ pathway largely depends on AKT phosphorylation. Cells with inactive or mutant 
BRCA1/2 (also called “BRCAness”) are unable to activate HR upon DSB damage (C). Instead, the DSBs are processed by 
either the nonmutagenic canonical NHEJ (C-NHEJ) pathway or the highly mutagenic alternative NHEJ (A-NHEJ) 
pathway (also known as microhomology-mediated end joining MMEJ). The subsequent genetic instability is probably 
one of the drivers of carcinogenesis in cells with homozygous BRCA1/2 mutations. Nuclease activity of MRE11 favors A-
NHEJ and requires the presence of PARP. The use of PARP inhibitors in cells with no or mutant BRCA1/2 leads to 
synthetic lethality of cancer cells (D). At least theoretically, this should particularly be true in cells with repressed C-
NHEJ pathway due to inactivation of proteins such as DNA-PK, KU70/80, Artemis, XRCC4, Ligase IV or to blocked AKT 
signaling. 
 
 
 
THE FAMILY OF PARP PROTEINS AND ALTERNATIVE ROLES 
Nuclear DNA-interacting proteins that are targets of poly-ADP ribosylation include core histones H1 
(chromatin relaxation), HMG proteins, topoisomerases I and II (genomic maintenance), WRN 
(several DNA repair pathways), DNA-PKcs/Ku70/Ku80 complex (NHEJ DNA repair pathway), ATM 
(HR pathway and checkpoint activation), MRE11 (HR pathway and restarting of the collapsed 
replication fork), and the well-known XRCC1/DNA ligase IIIlalpha/PolBeta complex (BER pathway). 
Since several proteins are targeted by poly-ADP ribosylation, PARP also participates in other key 
cellular functions than simply being DNA damage “sensors”. These other functions are cell death 
programs (PARP is cleaved by caspase-3 through the AIFdependant apoptosis pathway), 
transcription regulation, telomere cohesion and mitotic spindle formation during cell division (fall in 
ATP prevents cells with unrepaired DNA damaged from entering mitosis), intracellular energy 
metabolism, and intracellular trafficking of proteins such as p53,                and HMGB1 [13]. The 
many alternative functions are partly explained by the existence of least 17 members located on 
different regions of the human genome. Further complexity of PARP related functions has been 
explained by alternatively spliced transcript variants encoding different mRNA isoforms of several of 
the gene members. At least six of the PARP members are structurally related and subdivided in 3 
groups, with PARP1, 2 and 3 in the first group, 
PARP4 in the second and tankyrase 1 (TKNS) and TKNS2 in the third [14]. PARP1 and PARP2 are the 
most abundant proteins and represent the majority of large PAR activity in human cells. PARP1 and 
PARP2 are therefore the two most studied of all the PARP genes. 
PARP1 is considered to best characterize the activation of the BER pathway. The PARP1 gene is 
located on chromosome 1q43 and codes a protein whose molecular weight is 116 kDa. The PARP1 
protein carries 3 main domains, one N-terminal zinc-finger domain that detects and binds to DNA 
single strand breaks, one selfmodification inhibitory domain that carries poly(ADP)- ribosylation 
sites, and one C-terminal catalytic domain [9,15,16]. 
PARP2 corresponds to the C-terminal part of PARP1 (catalytic domain binding the NAD+), but it does 
not possess a Zn finger DNA binding domain and the central selfmodification domain found in 
PARP1. Although accounting for only a small part of the total poly-ADP ribosylation stimulated by 
DNA SSBs, PARP2 plays a role in genomic integrity maintenance as it interacts with PARP1 as a 
hétérodimère. Therefore, both proteins can modify themselves mutually through poly-ADP 
ribosylation. Interestingly, cells from PARP2-deficient mice treated with alkylating agents displayed 
delayed DNA strand break resealing similar to that observed in PARP1-deficient cells [17]. 
 
  
CONSEQUENCE OF PARP INHIBITION 
 
Since PARP proteins act as DNA damage “sensors” that allows modulation of BER capacity, PARP is a 
potential target for inhibition of DNA repair (Fig. 1). Modulation of poly-ADP ribosylation is 
therefore considered a promising approach in clinical practice [18]. As stated earlier, the loss or 
repression of PARP1 expression is sufficient to induce cell death in cancer cells bearing BRCA1 or 
BRCA2 homozygous mutations, which are rate-limiting genes in the HRR pathway [19]. This 
observed synthetic lethality has lead to innovative clinical perspectives. PARP inhibition also 
suggests a 
promising approach to sensitize tumor cells to chemo- and radiotherapy. 
The inactivation of PARP in mice has lead to increased sensitivity to ionizing radiation and alkylating 
agents and to genomic instability [15]. Although the mechanism is not fully understood, the affinity 
of PARP1 for platinum-modified DNA in vitro has been established using modified cisplatin 
analogues to synthesize 25 bp DNA duplexes carrying platinum intrastrand crosslinks [20]. The 
activation of PARP upon cisplatin treatment is poorly characterized, but PARP could facilitate the 
dissociation of nuclear proteins from platinum-modified DNA that in turn could facilitate 
recruitment of DNA repair proteins [21]. Recent work has shown that PARP1 inhibition influences 
DNA repair capacity of DNA platinum adducts with subsequent synergy with cisplatin treatment by 
inducing the intrinsic pathway of apoptosis [3,22]. The hypothesis that PARP1 is implicated in 
cisplatin resistance was further strengthened by recent work showing that PARP1 is highly 
expressed and constitutively hyperactivated in human ciplastinresistant cancer cells [4]. These cells 
with high levels of poly(ADPribosyl) ated proteins (high PARP1 activation) strongly induced 
apoptosis in response to pharmacologic PARP inhibitors suggesting  that the response to PARP 
inhibitors can, in several cases of platinum-refractivity, be predicted by the level of PAR activity. 
PARP inhibitors also have the capacity to radiosensitize cancer cells [23]. Further, the global 
expression pattern of the DNA repair proteins, such as PARP might have predictive implications in 
the adjuvant setting of NSCLC treatments. Interestingly, one study has linked a single nucleotide 
polymorphism (SNP) in the PARP1 gene with response of non-small cell lung cancers (NSCLC) to 
chemotherapy [24]. Our own recent studies have suggested that PARP1 tumor positivity might 
constitute a molecular context with theranostic interest when it is combined with ERCC1 and MSH2 
status in NSCLC, with histological subtypes as possible subgroups that should be studied separately 
[3,25]. Altogether, targeting PARP could become of large interest in treatment schedules of NSCLC. 
A valid definition of a “BRCAness” phenotype in NSCLC would help identifying patients who may 
respond optimally to PARP inhibitors.  
 
  
PARP INHIBITORS IN THE CLINIC 
Despite a large number of chemically distinct PARP inhibitors synthesized to date and explored for 
their putative therapeutic utility,only six have been tested in NSCLC (Table 1). Initially, preclinical 
studies suggested the potential efficacy of therapy combining PARP inhibitors with cisplatin in 
hepatocellular cancer [26]. In triple-negative breast cancer PARP inhibitors synergized with 
carboplatin plus gemcitabine [27,28]. PARP inhibitors that have been tested clinically in solid tumors 
as either monotherapy or in combination are olaparib (AZD2281), veliparib (ABT-888), iniparib (BSI-
201), AG-014699, PF01367338, MK-4827, and CEP-9722, and EISAI. 
 
Olaparib 
Olaparib (AZD2281, Astra Zeneca/ KuDOS) is an orally active PARP inhibitor. Initial in vitro study 
showed its activity in association with the alkylating agent methanesulphonate (MMS) and in vivo 
study confirmed the ability of the molecule to potentiate the antitumor activity of methylating 
chemotherapeutic agents as temozolomide without exacerbation of the systemic toxicity. BRCA 
deficient cell lines were hypersensitive to olaparib in comparison with BRCA 1 and 2 proficient cells 
[29]. The efficacy of the molecule in BRCA mutated tumors was reported in a phase I study where 
60 patients with solid tumors were enrolled; initially the study inclusion criteria didn’t require the 
presence of the mutation, while in the expansion phase only patients with a BRCA mutation were 
enrolled (n=22). The maximum administered dose of olaparib was 600 mg twice daily and the 
maximum tolerated dose was 400 mg twice daily. The pharmacokinetic study showed a rapid 
absorption of the drug (peak of plasma concentration observed between 1 and 3 hours) and a rapid 
elimination with a half life of approximately 5 to 7 hours. The most common adverse events were 
nausea, fatigue and vomiting, with a limited incidence of myelosuppression. No obvious increase in 
the frequency of grade of adverse events was observed comparing known BRCA1 or BRCA2 
mutation carriers with non carriers. A durable antitumor activity was observed in patients with a 
BRCA1 or BRCA2 mutation, or in patient with a 
family history of BRCA mutation: of the 19 BRCA carriers evaluable patients, 12 (63%) had a clinical 
benefit with a radiologic or tumor-marker response, while no objective antitumor responses were 
observed in patient without known BRCA mutations [30]. A multicenter, single arm, phase II study 
sought to test the efficacy of olaparib in refractory breast cancer with a confirmed BRCA1-2 
mutation and to evaluate the safety and the tolerability of the molecule. Such study was conducted 
in 54 patients (27 treated with olaparib 400 mg bid, 27 at the dose of 100 mg bid) with an 
objective response rate (ORR) of 41% and 22% respectively. PFS was 5.7 months in the cohort with 
400 mg bid and 3.8 in the cohort with 100mg bid [31,32]. A good tolerability of the treatment was 
reported with grade 3 or higher toxicities seen in 5 patients in terms of fatigue, nausea and anemia. 
The same study design was applied for a phase II study of olaparib in patients with refractory BRCA 
mutated ovarian cancer [33]. The first cohort (33 patients) was given daily olaparib at the dose of 
400 mg bid, and the second cohort (24 patients) was given continuous olaparib 100 mg bd. The ORR 
was 33% in the arm with 400 mg bid and 13% in the 100mg arm; the most frequently reported 
adverse events were nausea and fatigue. CTCAE grade 3 or 4 events were reported in 17 of 33 
patients in the olaparib 400 mg cohort and in 14 of 24 patients in the olaparib 100 mg cohort. 
The ICEBERG-3 study is a phase II open-label study, comparing the efficacy of olaparib to pegylated 
liposomial doxorubicin in ovarian cancer carrying the BRCA mutation that has recently completed 
the enrollment [34]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Olaparib is also tested in the maintenance setting; a phase II randomized trial of olaparib 
monotherapy as maintenance therapy after second-line platinum based therapy in platinum-
sensitive ovarian cancer has recently completed accrual and preliminary data were presented at 
the ASCO meeting 2011: the PFS by RECIST criteria was significantly longer in the olaparib 400 mg 
bid than the placebo group (HR, 0.35; 95% CI 0.25–0.49; P<0.00001; median 8.4 vs 4.8 months), 
with a toxicity profile similar to the previous studies [35]. 
 
Iniparib  
Iniparib (BSI-201) is a small molecule with very weak PARPinhibitory properties, and which real 
mechanism of action is yet to  be elucidated [36]. The safety, tolerability and efficacy of BSI-201 in 
monotherapy or in association with other chemotherapic agents in solid tumors (topotecan 1.5 
mg/mq; gemcitabine 1000 mg/mq; temozolomide 75 mg/mq or carboplatin AUC6 and paclitaxel 
200 mg/mq) was evaluated in different phase I trials [37,38]. In all the studies the treatment with 
BSI-201 was well tolerated with a maximum dose of BSI-201 administered of 8.0 mg/kg twice 
weekly; in the Mahany’s study all the patients tolerated doses up to 5.6 mg/kg with two serious 
adverse events possibly related to iniparib. A randomized phase II study in triple negative breast 
cancer evaluated the efficacy of carboplatin AUC2 and gemcitabine 1000 mg/mg (administered on 
days 1 and 8 every 21 days) alone or in association with BSI-201 (at 5,6 mg/kg e.v. biweekly on 
days 1, 4, 8 and 11); the trial showed an efficacy of the experimental arm, with a clinical benefits 
rate of 12% for the control arm and 52% for the experimental arm (clinical benefits encompassed 
a complete response, a partial response, or a stable disease). The progression free survival was 6,9 
months for the experimental arm and 3,3 months for the control arm (p<0.0001, HR=0,342 CI 0.2-
0.584) and overall survival 9,2 versus 5,7 months (p=0.0005, HR= 0,348 CI 0,189-0,649) [39]. In 
December 2009 at the San Antonio Breast Cancer Symposium results updated showed an overall 
survival of the chemotherapy arm of 7,7 months and 12,2 for the association arm (p= 0.005; HR= 
0,5; 95% CI 0.30-0.82) [40]. According to these data a phase III trial to evaluate the efficacy of 
iniparib in association with chemotherapy in patients with triple negative breast cancer previously 
treated or in first line was conducted. The results were presented in 2011 at the ASCO meeting in 
Chicago and the key end points were not met: the PFS was 5,1 months for the patients in the 
experimental arm and 4,1 months in the control arm (p= 0,027; HR: 0,79; 95% CI 0,646-0,976) and 
the OS was 11,8 versus 11,1 months (p= 0,28; HR: 0,87; 95% CI 0,687- 1,116). No differences were 
observed in terms of response rate between the two arms and the study confirmed the good 
profile of tolerability and toxicity of iniparib. An exploratory analysis showed a possible benefit for 
the use of iniparib in association with chemotherapy in second and third line [41]. 
Iniparib appeared to potentiate the anti-tumor activity of chemotherapy also in patients with 
ovarian cancer, either sensitive or not to cisplatin and two abstracts were presented at the ASCO 
meeting in 2011. A phase II study in platinum sensitive patients, demonstrated that the 
combination of carboplatin (AUC 4 d1), gemcitabine (1000 mg/mq d1,8) and iniparib (5,6 mg/Kg 
d1,4,8,11) achieved an overall response rate of 70,6%, that is better than the 47% reported in 
literature [42,43]. In the second phase II trial in patients with platinum resistant ovarian cancer the 
association of iniparib with the chemotherapy showed a progression free survival and an overall 
response rate in line with those achieved with the pegylated liposomal doxorubicine (ORR: 31,6% 
versus 11,7%; PFS: 5,9 versus 3,1 months) [44,45]. 
 
Other PARP Inhibitors 
The first phase I in human of a PARP inhibitor was the molecule AG014699 (Pfizer) in association 
with temozolomide in a total of 33 patients with solid tumors. In the first part of the trial the 
primary objective was to find the PARP inhibitory dose (PID), based  on 74-97% inhibition of 
peripheral blood lymphocyte (PBL). The PID was 12 mg/mq and no dose-limiting toxicities were 
observed [46,47]. Subsequently, AG014699 was tested with temozolomide 200 mg/mq daily for 5 
days every 4 weeks; a further dose increase of AG014699 to 18 mg/mq was evaluated without any 
additional evidence of PARP inhibition, however the dose was intolerable with a significant rate of 
myelosuppresion. Responses were seen in patients with melanoma, desmoids tumors, pancreas 
cancer, leyomiosarcoma and prostate cancer.  
The phase II study of AG014699 12 mg/mq with temozolomide 200 mg/mq in patient with 
metastatic melanoma showed a partial response rate of 18% and a prolonged disease stabilization 
(>6 months); however an increased frequency of myelosuppresion was found, with a 12-15% of 
cycles with grade 4 neutropenia and thrombocytopenia reported, necessitating a 25% dose 
reduction [48]. A phase II of AG014699 in combination with cisplatin in triple negative breast 
cancer is ongoing. 
Veliparib (ABT-888; Abbott Laboratories) is the first compound tested in a phase 0 clinical trial 
with target modulation as primary end point in patients with advanced tumors; trial objectives 
were to evaluate its pharmacokinetic and the pharmacodynamic and to determine a dose range at 
which ABT-888 inhibits PARP in tumor tissue and PBMC. The study demonstrated that ABT-888 is 
rapidly absorbed, with a peak plasma level between 0.5 and 1.5 hours after dosing, with a 
clearance after 24 h of dosing. PARP inhibition of >85% lasting up to 24h post drug administration 
was observed in tumor tissue and PBMC at the dose of 25 and 50mg [49]. 
Several phase I studies investigated the DLT and the MTD of veliparib monotherapy or in 
combination with chemotherapic regimes (carboplatin and paclitaxel, carboplatin and gemcitabine 
or carboplatin monotherapy) in patients with advanced solid tumors (included NSCLC) or with 
BRCA-associated tumors, with the evidence of a well-tolerated drug with a safety profile [50-54]. 
MK-4827 (Merck) is a selective PARP 1-2 inhibitor tested in a phase I clinical trials in patients with 
BRCA-deficient and sporadic ovarian cancers. Dose-limiting toxicity was observed in 3 patients 
(grade 3 fatigue, pneumonitis and anorexia) and the antitumor activity was observed both in 
sporadic and BRCA-deficient cancers [55].  
Two clinical trials are still ongoing with MK-4827, one is a phase I study in patients with solid 
tumors, and the other in association with temozolomide in advanced cancers. Eisai PARP inhibitor 
E7016 was reported at the EORTC-NCI-AACR 2012 meeting in combination with Temozolomide 
[56]. 
 
PARP INHIBITORS AND NSCLC 
A phase Ib study, presented at the ASCO meeting 2011, evaluating the activity of iniparib 5,6 
mg/kg d1,4,8,11 in association with carboplatin AUC 6 d1 and paclitaxel 200 mg/mq d1 in first line 
treatment, showed a promising activity of this combination, with an increased overall response 
rate compared with previous studies with carboplatin and paclitaxel alone (20% versus 15%) in 
patients with stage IIIB-IV non-small cell lung cancer (NSCLC) . Three patients had a confirmed 
partial response, 9 patients showed a stable disease (6 through 12 weeks and 3 through 18 weeks) 
with only a progressive disease. The most common toxicities were grade 1-2 asthenia (40%), 
anemia (33,3%) and nausea (26,7); grade 3-4 adverse events were exclusively neutropenia (13,3%) 
and anemia (6,7%) [57]. 
At the IASLC (International Association for the study of Lung Cancer) meeting in Amsterdam in 
2011 the preliminary results of a randomized (2:1), open label phase II trial of gemcitabine 1250 
mg/mq (d1 and 8) in association with cisplatin 75 mg/mq (d1) with or without iniparib 5,6 mg/kg 
(d 1,4,8,11) in first line treatment in patients with NSCLC were presented (Fig. 2). One hundred 
and nineteen patients were enrolled, 80 treated in the experimental arm and 39 in the control 
one; primary end-point was the ORR, secondary: PFS, OS, and safety of this combination. The 
overall response rate for the iniparib arm was 21% (with one case of complete response) and 26% 
for the control arm and no differences in response by subgroups were seen. The preliminary 
results of progression free survival showed a not statistically significant trend in favor of the 
experimental arm with iniparib (5,7 vs 4,3 months, p: 0,145, HR: 0,69, 95% CI: 0,43-1,14); while the 
toxicity profile of the combination of cisplatin, gemcitabine and iniparib was similar to the one 
observed with cisplatin and gemcitabine alone, with asthenia, nausea and neutropenia as most 
common averse events (neutropenia was the most frequent grade 3-4 adverse events in both 
arms). The authors recommended caution in the interpretation of the advantage in terms of 
progression free survival, because the two groups were imbalanced in performance status and 
gender distribution [58]. 
Mature results for overall and progression free survival will be presented soon. The ECLIPSE study 
was a phase III trial to evaluate (as primary end point) the overall survival (OS) of patients with 
advanced squamous cell lung cancer receiving a combination of carboplatin gemcitabine either 
with or without BSI-201 in first line (Fig. 3). Eight hundred twenty-five patients were planned to be 
treated with a 1:1 randomization schema and they were planned to receive carboplatin AUC5 d1- 
gemcitabine 1000 mg/mq d 1,8 either with or without iniparib 5,6 mg/kg d1,4,8,11 every three 
weeks. Secondary endpoints of the study were: progression free survival (PFS), time to progression 
(TTP), overall response rate (ORR) and safety and tolerability of the treatment. A recent press 
release announced that the trial did not achieve an improvement in overall survival and there 
were no meaningful differences in the main safety parameters between the two arms [59]. Two 
clinical trials are evaluating the role of olaparib in patients with NSCLC: one is a phase I trial of 
olaparib in association or not with cisplatin and concurrent radiotherapy in locally advanced 
disease, the other is a randomized phase Ib/II open label study, designed to evaluate the efficacy 
and tolerability of gefitinib with or without olaparib in patients with NSCLC harboring the 
Epidermal Growth Factor Recptor (EGFR) mutation (Table 2). Veliparib (ABT-888) is under 
investigation in NSCLC in three ongoing clinical trials: one is phase I-II trial evaluating the DLT and 
PFS of veliparib in association with carboplatin/paclitaxel, with or without radiation therapy in 
patients with stage III NSCLC that cannot underwent surgery, the second one is a phase I trial with 
cisplatin and gemcitabine in NSCLC, biliary, pancreatic or urothelial cancer. 
  
 
 
 
 
 
 
 
 
Fig. (2). Study design of the phase II trial of iniparib in NSCLC. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
A randomized phase II, double-blind, dose ranging trial is evaluating the safety and the efficacy of 
veliparib and whole brain radiation therapy in subjects with brain metastases from NSCLC (Table 
2). 
 
CONCLUSION 
Results from preclinical studies and first clinical trial showed promising data about the possible 
role of PARP inhibitors in association with standard chemotherapies regimes. However, recent 
results have challenged the PARP-inhibitory nature of iniparib and the PK profile of olaparib is 
currently been reassessed. Preliminary data in lung cancer showed an activity of iniparib in 
association with cisplatin/gemcitabine, but not a statistically advantage in terms of progression 
free survival; more information will be available deriving from the final results of the phase III trial, 
although preliminary data are not completely encouraging. 
Many questions are still open, such as the potential patients that could more benefit from these 
molecules, the line of therapy in which these drugs can be used and the optimal chemotherapy 
regimens associated. A major challenge in the next years is also to identify the presence of tumors 
with a BRCAness features, that potentially could benefit of this treatment together with the 
discovery of new predictive biomarkers. 
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